Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of XXXX .

@entity1 @entity778 @entity13923 @entity137 @entity19 @entity5434 @entity12638 @entity35
Avian influenza virus (H5N1) has caused serious infections in @entity1 beings. This virus has the potential to emerge as a pandemic threat in @entity1 . Effective vaccines against @entity778 are needed. A recombinant @entity12638 baculovirus, Bmg64HA, was constructed for the expression of HA protein of H5N1 influenza virus displaying on the viral envelope surface. The HA protein accounted for approximately 3% of the total viral proteins in @entity12638 pupae infected with the recombinant virus. Using a series of separation and purification methods, pure Bmgp64HA virus was isolated from these @entity12638 pupae bioreactors. @entity13923 adjuvant was used for an H5N1 influenza vaccine. Immunization with this vaccine at doses of 2 mg/kg and 0.67 mg/kg was carried out to induce the production of neutralizing antibodies, which protected monkeys against @entity778 . At these doses, the vaccine induced 1:40 antibody titers in 50% and 67% of the monkeys, respectively. The results of safety evaluation indicated that the vaccine did not cause any @entity137 at the dosage as large as 3.2 mg/kg in @entity5434 and 1.6 mg/kg in @entity19 . The results of dose safety evaluation of vaccine indicated that the safe dose of the vaccine were higher than 0.375 mg/kg in @entity35 and 3.2 mg/kg in @entity5434 . Our work showed the vaccine may be a candidate for a highly effective, cheap, and safe influenza vaccine for use in @entity1 .
